FDA Readies New Guidance and User Fee Program for Biosimilars: Drug interchangeability and user fees are contentious issues the FDA must resolve. Is the FDA up to the task?

Autor:	Stephen, Barlas
Rok vydání:	2012
Předmět:	FDA Readies New Guidance and User Fee Program for Biosimilars
Zdroj:	Biotechnology healthcare. 9(2)
ISSN:	1554-169X
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=pmid________::61d3dbf161f9b6852914c48a47946a90 https://pubmed.ncbi.nlm.nih.gov/22876212 Zobrazit plný text záznamu